nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—CYP2D6—Niacin—coronary artery disease	0.08	0.173	CbGbCtD
Methylnaltrexone—CYP2D6—Timolol—coronary artery disease	0.0744	0.161	CbGbCtD
Methylnaltrexone—CYP2D6—Captopril—coronary artery disease	0.0655	0.141	CbGbCtD
Methylnaltrexone—CYP2D6—Simvastatin—coronary artery disease	0.0632	0.137	CbGbCtD
Methylnaltrexone—CYP2D6—Pravastatin—coronary artery disease	0.0619	0.134	CbGbCtD
Methylnaltrexone—CYP2D6—Lovastatin—coronary artery disease	0.0619	0.134	CbGbCtD
Methylnaltrexone—CYP2D6—Atorvastatin—coronary artery disease	0.0564	0.122	CbGbCtD
Methylnaltrexone—Naloxone—CREB1—coronary artery disease	0.00301	0.191	CrCbGaD
Methylnaltrexone—Nalbuphine—OPRD1—coronary artery disease	0.00198	0.125	CrCbGaD
Methylnaltrexone—Oxymorphone—OPRD1—coronary artery disease	0.00161	0.102	CrCbGaD
Methylnaltrexone—Naltrexone—OPRD1—coronary artery disease	0.00161	0.102	CrCbGaD
Methylnaltrexone—Hydrocodone—OPRD1—coronary artery disease	0.00141	0.0894	CrCbGaD
Methylnaltrexone—Pain—Rosuvastatin—coronary artery disease	0.00132	0.00416	CcSEcCtD
Methylnaltrexone—Oedema—Clopidogrel—coronary artery disease	0.00132	0.00415	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Fenofibrate—coronary artery disease	0.00132	0.00414	CcSEcCtD
Methylnaltrexone—Erythema—Enalapril—coronary artery disease	0.00131	0.00413	CcSEcCtD
Methylnaltrexone—Skin disorder—Fenofibrate—coronary artery disease	0.0013	0.0041	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Eplerenone—coronary artery disease	0.0013	0.0041	CcSEcCtD
Methylnaltrexone—Flatulence—Trandolapril—coronary artery disease	0.0013	0.00409	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Fenofibrate—coronary artery disease	0.0013	0.00408	CcSEcCtD
Methylnaltrexone—Erythema—Telmisartan—coronary artery disease	0.00129	0.00408	CcSEcCtD
Methylnaltrexone—Flatulence—Enalapril—coronary artery disease	0.00129	0.00407	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Clopidogrel—coronary artery disease	0.00129	0.00407	CcSEcCtD
Methylnaltrexone—Oxycodone—OPRD1—coronary artery disease	0.00129	0.0816	CrCbGaD
Methylnaltrexone—Skin disorder—Clopidogrel—coronary artery disease	0.00128	0.00403	CcSEcCtD
Methylnaltrexone—Flatulence—Telmisartan—coronary artery disease	0.00128	0.00402	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Rosuvastatin—coronary artery disease	0.00126	0.00398	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Ezetimibe—coronary artery disease	0.00126	0.00397	CcSEcCtD
Methylnaltrexone—Skin disorder—Ezetimibe—coronary artery disease	0.00125	0.00393	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Eplerenone—coronary artery disease	0.00123	0.00388	CcSEcCtD
Methylnaltrexone—Oedema—Simvastatin—coronary artery disease	0.00122	0.00386	CcSEcCtD
Methylnaltrexone—Nausea—Penbutolol—coronary artery disease	0.00122	0.00385	CcSEcCtD
Methylnaltrexone—Erythema—Perindopril—coronary artery disease	0.00122	0.00385	CcSEcCtD
Methylnaltrexone—Abdominal pain—Rosuvastatin—coronary artery disease	0.00122	0.00385	CcSEcCtD
Methylnaltrexone—Skin disorder—Eplerenone—coronary artery disease	0.00122	0.00385	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Eplerenone—coronary artery disease	0.00122	0.00383	CcSEcCtD
Methylnaltrexone—Flatulence—Perindopril—coronary artery disease	0.0012	0.00379	CcSEcCtD
Methylnaltrexone—Diarrhoea—Gemfibrozil—coronary artery disease	0.0012	0.00379	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Valsartan—coronary artery disease	0.0012	0.00377	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Olmesartan—coronary artery disease	0.00119	0.00376	CcSEcCtD
Methylnaltrexone—Erythema—Furosemide—coronary artery disease	0.00119	0.00374	CcSEcCtD
Methylnaltrexone—Buprenorphine—OPRD1—coronary artery disease	0.00118	0.0752	CrCbGaD
Methylnaltrexone—Naloxone—OPRD1—coronary artery disease	0.00118	0.0746	CrCbGaD
Methylnaltrexone—Diarrhoea—Ticagrelor—coronary artery disease	0.00117	0.0037	CcSEcCtD
Methylnaltrexone—Flatulence—Furosemide—coronary artery disease	0.00117	0.00369	CcSEcCtD
Methylnaltrexone—Hydromorphone—OPRD1—coronary artery disease	0.00117	0.0741	CrCbGaD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Niacin—coronary artery disease	0.00117	0.00367	CcSEcCtD
Methylnaltrexone—Dizziness—Gemfibrozil—coronary artery disease	0.00116	0.00366	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Fenofibrate—coronary artery disease	0.00116	0.00365	CcSEcCtD
Methylnaltrexone—Oedema—Valsartan—coronary artery disease	0.00116	0.00364	CcSEcCtD
Methylnaltrexone—Oedema—Olmesartan—coronary artery disease	0.00115	0.00363	CcSEcCtD
Methylnaltrexone—Pain—Fenofibrate—coronary artery disease	0.00115	0.00361	CcSEcCtD
Methylnaltrexone—Erythema—Losartan—coronary artery disease	0.00115	0.00361	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Clopidogrel—coronary artery disease	0.00114	0.00358	CcSEcCtD
Methylnaltrexone—Dizziness—Ticagrelor—coronary artery disease	0.00114	0.00358	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Valsartan—coronary artery disease	0.00113	0.00357	CcSEcCtD
Methylnaltrexone—Flatulence—Losartan—coronary artery disease	0.00113	0.00356	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Olmesartan—coronary artery disease	0.00113	0.00356	CcSEcCtD
Methylnaltrexone—Pain—Clopidogrel—coronary artery disease	0.00113	0.00355	CcSEcCtD
Methylnaltrexone—Oedema—Niacin—coronary artery disease	0.00112	0.00354	CcSEcCtD
Methylnaltrexone—Skin disorder—Valsartan—coronary artery disease	0.00112	0.00354	CcSEcCtD
Methylnaltrexone—Pain—Lovastatin—coronary artery disease	0.00112	0.00353	CcSEcCtD
Methylnaltrexone—Skin disorder—Olmesartan—coronary artery disease	0.00112	0.00352	CcSEcCtD
Methylnaltrexone—Vomiting—Gemfibrozil—coronary artery disease	0.00112	0.00352	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Trandolapril—coronary artery disease	0.00111	0.00351	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Olmesartan—coronary artery disease	0.00111	0.0035	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Ezetimibe—coronary artery disease	0.00111	0.00349	CcSEcCtD
Methylnaltrexone—Oedema—Pravastatin—coronary artery disease	0.00111	0.00349	CcSEcCtD
Methylnaltrexone—Pain—Ezetimibe—coronary artery disease	0.0011	0.00346	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Fenofibrate—coronary artery disease	0.0011	0.00345	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Telmisartan—coronary artery disease	0.00109	0.00345	CcSEcCtD
Methylnaltrexone—Skin disorder—Niacin—coronary artery disease	0.00109	0.00344	CcSEcCtD
Methylnaltrexone—Vomiting—Ticagrelor—coronary artery disease	0.00109	0.00344	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Niacin—coronary artery disease	0.00109	0.00342	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Eplerenone—coronary artery disease	0.00109	0.00342	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Clopidogrel—coronary artery disease	0.00108	0.0034	CcSEcCtD
Methylnaltrexone—Oedema—Trandolapril—coronary artery disease	0.00108	0.00339	CcSEcCtD
Methylnaltrexone—Pain—Eplerenone—coronary artery disease	0.00107	0.00339	CcSEcCtD
Methylnaltrexone—Oedema—Enalapril—coronary artery disease	0.00107	0.00337	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Lovastatin—coronary artery disease	0.00107	0.00337	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Pravastatin—coronary artery disease	0.00107	0.00337	CcSEcCtD
Methylnaltrexone—Abdominal pain—Fenofibrate—coronary artery disease	0.00106	0.00334	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Simvastatin—coronary artery disease	0.00106	0.00333	CcSEcCtD
Methylnaltrexone—Diarrhoea—Rosuvastatin—coronary artery disease	0.00106	0.00333	CcSEcCtD
Methylnaltrexone—Oedema—Telmisartan—coronary artery disease	0.00106	0.00333	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Trandolapril—coronary artery disease	0.00105	0.00332	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Ezetimibe—coronary artery disease	0.00105	0.00331	CcSEcCtD
Methylnaltrexone—Pain—Simvastatin—coronary artery disease	0.00105	0.0033	CcSEcCtD
Methylnaltrexone—Skin disorder—Trandolapril—coronary artery disease	0.00104	0.00329	CcSEcCtD
Methylnaltrexone—Nausea—Gemfibrozil—coronary artery disease	0.00104	0.00329	CcSEcCtD
Methylnaltrexone—Abdominal pain—Clopidogrel—coronary artery disease	0.00104	0.00328	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Trandolapril—coronary artery disease	0.00104	0.00327	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Telmisartan—coronary artery disease	0.00104	0.00326	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Enalapril—coronary artery disease	0.00104	0.00326	CcSEcCtD
Methylnaltrexone—Abdominal pain—Lovastatin—coronary artery disease	0.00104	0.00326	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Perindopril—coronary artery disease	0.00103	0.00325	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Eplerenone—coronary artery disease	0.00103	0.00324	CcSEcCtD
Methylnaltrexone—Diarrhoea—Acetylsalicylic acid—coronary artery disease	0.00103	0.00323	CcSEcCtD
Methylnaltrexone—Skin disorder—Telmisartan—coronary artery disease	0.00103	0.00323	CcSEcCtD
Methylnaltrexone—Dizziness—Rosuvastatin—coronary artery disease	0.00102	0.00322	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Telmisartan—coronary artery disease	0.00102	0.00322	CcSEcCtD
Methylnaltrexone—Nausea—Ticagrelor—coronary artery disease	0.00102	0.00321	CcSEcCtD
Methylnaltrexone—Abdominal pain—Ezetimibe—coronary artery disease	0.00102	0.0032	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Furosemide—coronary artery disease	0.001	0.00316	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Simvastatin—coronary artery disease	0.001	0.00315	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Valsartan—coronary artery disease	0.000999	0.00315	CcSEcCtD
Methylnaltrexone—Oedema—Perindopril—coronary artery disease	0.000997	0.00314	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Olmesartan—coronary artery disease	0.000994	0.00313	CcSEcCtD
Methylnaltrexone—Abdominal pain—Eplerenone—coronary artery disease	0.000994	0.00313	CcSEcCtD
Methylnaltrexone—Dizziness—Acetylsalicylic acid—coronary artery disease	0.000993	0.00313	CcSEcCtD
Methylnaltrexone—Pain—Olmesartan—coronary artery disease	0.000984	0.0031	CcSEcCtD
Methylnaltrexone—Erythema—Ramipril—coronary artery disease	0.000983	0.0031	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Perindopril—coronary artery disease	0.000978	0.00308	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Niacin—coronary artery disease	0.000971	0.00306	CcSEcCtD
Methylnaltrexone—Skin disorder—Perindopril—coronary artery disease	0.000969	0.00305	CcSEcCtD
Methylnaltrexone—Abdominal pain—Simvastatin—coronary artery disease	0.000968	0.00305	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Perindopril—coronary artery disease	0.000964	0.00304	CcSEcCtD
Methylnaltrexone—Pain—Niacin—coronary artery disease	0.000962	0.00303	CcSEcCtD
Methylnaltrexone—Erythema—Timolol—coronary artery disease	0.000961	0.00303	CcSEcCtD
Methylnaltrexone—Vomiting—Acetylsalicylic acid—coronary artery disease	0.000954	0.00301	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Furosemide—coronary artery disease	0.000951	0.00299	CcSEcCtD
Methylnaltrexone—Pain—Pravastatin—coronary artery disease	0.000947	0.00298	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Valsartan—coronary artery disease	0.000946	0.00298	CcSEcCtD
Methylnaltrexone—Skin disorder—Furosemide—coronary artery disease	0.000942	0.00297	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Olmesartan—coronary artery disease	0.000941	0.00296	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Furosemide—coronary artery disease	0.000937	0.00295	CcSEcCtD
Methylnaltrexone—Oedema—Losartan—coronary artery disease	0.000935	0.00295	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Trandolapril—coronary artery disease	0.000928	0.00292	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Niacin—coronary artery disease	0.00092	0.0029	CcSEcCtD
Methylnaltrexone—Nausea—Rosuvastatin—coronary artery disease	0.000918	0.00289	CcSEcCtD
Methylnaltrexone—Diarrhoea—Fenofibrate—coronary artery disease	0.000918	0.00289	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Losartan—coronary artery disease	0.000917	0.00289	CcSEcCtD
Methylnaltrexone—Abdominal pain—Valsartan—coronary artery disease	0.000914	0.00288	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Telmisartan—coronary artery disease	0.000912	0.00287	CcSEcCtD
Methylnaltrexone—Abdominal pain—Olmesartan—coronary artery disease	0.00091	0.00287	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Pravastatin—coronary artery disease	0.000905	0.00285	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Losartan—coronary artery disease	0.000904	0.00285	CcSEcCtD
Methylnaltrexone—Pain—Telmisartan—coronary artery disease	0.000903	0.00285	CcSEcCtD
Methylnaltrexone—Diarrhoea—Clopidogrel—coronary artery disease	0.000902	0.00284	CcSEcCtD
Methylnaltrexone—Diarrhoea—Lovastatin—coronary artery disease	0.000896	0.00282	CcSEcCtD
Methylnaltrexone—Nausea—Acetylsalicylic acid—coronary artery disease	0.000892	0.00281	CcSEcCtD
Methylnaltrexone—Erythema—Lisinopril—coronary artery disease	0.000891	0.00281	CcSEcCtD
Methylnaltrexone—Abdominal pain—Niacin—coronary artery disease	0.000889	0.0028	CcSEcCtD
Methylnaltrexone—Dizziness—Fenofibrate—coronary artery disease	0.000887	0.00279	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Trandolapril—coronary artery disease	0.000879	0.00277	CcSEcCtD
Methylnaltrexone—Diarrhoea—Ezetimibe—coronary artery disease	0.000879	0.00277	CcSEcCtD
Methylnaltrexone—Flatulence—Lisinopril—coronary artery disease	0.000878	0.00277	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Enalapril—coronary artery disease	0.000876	0.00276	CcSEcCtD
Methylnaltrexone—Abdominal pain—Pravastatin—coronary artery disease	0.000875	0.00276	CcSEcCtD
Methylnaltrexone—Dizziness—Clopidogrel—coronary artery disease	0.000872	0.00275	CcSEcCtD
Methylnaltrexone—Dizziness—Lovastatin—coronary artery disease	0.000866	0.00273	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Telmisartan—coronary artery disease	0.000864	0.00272	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Perindopril—coronary artery disease	0.000861	0.00271	CcSEcCtD
Methylnaltrexone—Diarrhoea—Eplerenone—coronary artery disease	0.00086	0.00271	CcSEcCtD
Methylnaltrexone—Pain—Perindopril—coronary artery disease	0.000853	0.00269	CcSEcCtD
Methylnaltrexone—Vomiting—Fenofibrate—coronary artery disease	0.000853	0.00269	CcSEcCtD
Methylnaltrexone—Abdominal pain—Trandolapril—coronary artery disease	0.00085	0.00268	CcSEcCtD
Methylnaltrexone—Dizziness—Ezetimibe—coronary artery disease	0.000849	0.00268	CcSEcCtD
Methylnaltrexone—Abdominal pain—Enalapril—coronary artery disease	0.000847	0.00267	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Captopril—coronary artery disease	0.00084	0.00265	CcSEcCtD
Methylnaltrexone—Vomiting—Clopidogrel—coronary artery disease	0.000838	0.00264	CcSEcCtD
Methylnaltrexone—Diarrhoea—Simvastatin—coronary artery disease	0.000838	0.00264	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Furosemide—coronary artery disease	0.000837	0.00264	CcSEcCtD
Methylnaltrexone—Abdominal pain—Telmisartan—coronary artery disease	0.000835	0.00263	CcSEcCtD
Methylnaltrexone—Vomiting—Lovastatin—coronary artery disease	0.000833	0.00262	CcSEcCtD
Methylnaltrexone—Dizziness—Eplerenone—coronary artery disease	0.000831	0.00262	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Ramipril—coronary artery disease	0.000831	0.00262	CcSEcCtD
Methylnaltrexone—Pain—Furosemide—coronary artery disease	0.000829	0.00261	CcSEcCtD
Methylnaltrexone—Vomiting—Ezetimibe—coronary artery disease	0.000817	0.00257	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Perindopril—coronary artery disease	0.000816	0.00257	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Timolol—coronary artery disease	0.000812	0.00256	CcSEcCtD
Methylnaltrexone—Abdominal pain—Captopril—coronary artery disease	0.000812	0.00256	CcSEcCtD
Methylnaltrexone—Dizziness—Simvastatin—coronary artery disease	0.00081	0.00255	CcSEcCtD
Methylnaltrexone—Oedema—Ramipril—coronary artery disease	0.000802	0.00253	CcSEcCtD
Methylnaltrexone—Pain—Losartan—coronary artery disease	0.0008	0.00252	CcSEcCtD
Methylnaltrexone—Vomiting—Eplerenone—coronary artery disease	0.000799	0.00252	CcSEcCtD
Methylnaltrexone—Nausea—Fenofibrate—coronary artery disease	0.000797	0.00251	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Furosemide—coronary artery disease	0.000793	0.0025	CcSEcCtD
Methylnaltrexone—Diarrhoea—Valsartan—coronary artery disease	0.000791	0.00249	CcSEcCtD
Methylnaltrexone—Abdominal pain—Perindopril—coronary artery disease	0.000788	0.00248	CcSEcCtD
Methylnaltrexone—Diarrhoea—Olmesartan—coronary artery disease	0.000788	0.00248	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Ramipril—coronary artery disease	0.000787	0.00248	CcSEcCtD
Methylnaltrexone—Oedema—Timolol—coronary artery disease	0.000784	0.00247	CcSEcCtD
Methylnaltrexone—Nausea—Clopidogrel—coronary artery disease	0.000783	0.00247	CcSEcCtD
Methylnaltrexone—Skin disorder—Ramipril—coronary artery disease	0.000779	0.00245	CcSEcCtD
Methylnaltrexone—Vomiting—Simvastatin—coronary artery disease	0.000779	0.00245	CcSEcCtD
Methylnaltrexone—Nausea—Lovastatin—coronary artery disease	0.000778	0.00245	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Ramipril—coronary artery disease	0.000775	0.00244	CcSEcCtD
Methylnaltrexone—Diarrhoea—Niacin—coronary artery disease	0.000769	0.00242	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Timolol—coronary artery disease	0.000769	0.00242	CcSEcCtD
Methylnaltrexone—Abdominal pain—Furosemide—coronary artery disease	0.000766	0.00241	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Losartan—coronary artery disease	0.000765	0.00241	CcSEcCtD
Methylnaltrexone—Dizziness—Valsartan—coronary artery disease	0.000765	0.00241	CcSEcCtD
Methylnaltrexone—Nausea—Ezetimibe—coronary artery disease	0.000763	0.0024	CcSEcCtD
Methylnaltrexone—Skin disorder—Timolol—coronary artery disease	0.000762	0.0024	CcSEcCtD
Methylnaltrexone—Dizziness—Olmesartan—coronary artery disease	0.000761	0.0024	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Timolol—coronary artery disease	0.000758	0.00239	CcSEcCtD
Methylnaltrexone—Diarrhoea—Pravastatin—coronary artery disease	0.000758	0.00239	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	0.000754	0.00237	CcSEcCtD
Methylnaltrexone—Nausea—Eplerenone—coronary artery disease	0.000747	0.00235	CcSEcCtD
Methylnaltrexone—Dizziness—Niacin—coronary artery disease	0.000744	0.00234	CcSEcCtD
Methylnaltrexone—Abdominal pain—Losartan—coronary artery disease	0.00074	0.00233	CcSEcCtD
Methylnaltrexone—Diarrhoea—Trandolapril—coronary artery disease	0.000736	0.00232	CcSEcCtD
Methylnaltrexone—Vomiting—Valsartan—coronary artery disease	0.000735	0.00232	CcSEcCtD
Methylnaltrexone—Diarrhoea—Enalapril—coronary artery disease	0.000733	0.00231	CcSEcCtD
Methylnaltrexone—Dizziness—Pravastatin—coronary artery disease	0.000732	0.00231	CcSEcCtD
Methylnaltrexone—Vomiting—Olmesartan—coronary artery disease	0.000732	0.00231	CcSEcCtD
Methylnaltrexone—Nausea—Simvastatin—coronary artery disease	0.000728	0.00229	CcSEcCtD
Methylnaltrexone—Oedema—Lisinopril—coronary artery disease	0.000727	0.00229	CcSEcCtD
Methylnaltrexone—Diarrhoea—Telmisartan—coronary artery disease	0.000723	0.00228	CcSEcCtD
Methylnaltrexone—Vomiting—Niacin—coronary artery disease	0.000715	0.00225	CcSEcCtD
Methylnaltrexone—Dizziness—Trandolapril—coronary artery disease	0.000711	0.00224	CcSEcCtD
Methylnaltrexone—Dizziness—Enalapril—coronary artery disease	0.000708	0.00223	CcSEcCtD
Methylnaltrexone—Skin disorder—Lisinopril—coronary artery disease	0.000707	0.00223	CcSEcCtD
Methylnaltrexone—Vomiting—Pravastatin—coronary artery disease	0.000704	0.00222	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Lisinopril—coronary artery disease	0.000703	0.00221	CcSEcCtD
Methylnaltrexone—Diarrhoea—Captopril—coronary artery disease	0.000703	0.00221	CcSEcCtD
Methylnaltrexone—Dizziness—Telmisartan—coronary artery disease	0.000699	0.0022	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Ramipril—coronary artery disease	0.000693	0.00218	CcSEcCtD
Methylnaltrexone—Nausea—Valsartan—coronary artery disease	0.000687	0.00216	CcSEcCtD
Methylnaltrexone—Nausea—Olmesartan—coronary artery disease	0.000684	0.00215	CcSEcCtD
Methylnaltrexone—Vomiting—Trandolapril—coronary artery disease	0.000684	0.00215	CcSEcCtD
Methylnaltrexone—Diarrhoea—Perindopril—coronary artery disease	0.000682	0.00215	CcSEcCtD
Methylnaltrexone—Vomiting—Enalapril—coronary artery disease	0.000681	0.00214	CcSEcCtD
Methylnaltrexone—Dizziness—Captopril—coronary artery disease	0.000679	0.00214	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Timolol—coronary artery disease	0.000677	0.00213	CcSEcCtD
Methylnaltrexone—Vomiting—Telmisartan—coronary artery disease	0.000672	0.00212	CcSEcCtD
Methylnaltrexone—Pain—Timolol—coronary artery disease	0.000671	0.00211	CcSEcCtD
Methylnaltrexone—Nausea—Niacin—coronary artery disease	0.000668	0.0021	CcSEcCtD
Methylnaltrexone—Diarrhoea—Furosemide—coronary artery disease	0.000663	0.00209	CcSEcCtD
Methylnaltrexone—Dizziness—Perindopril—coronary artery disease	0.00066	0.00208	CcSEcCtD
Methylnaltrexone—Nausea—Pravastatin—coronary artery disease	0.000658	0.00207	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Ramipril—coronary artery disease	0.000656	0.00207	CcSEcCtD
Methylnaltrexone—Vomiting—Captopril—coronary artery disease	0.000653	0.00206	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Timolol—coronary artery disease	0.000641	0.00202	CcSEcCtD
Methylnaltrexone—Dizziness—Furosemide—coronary artery disease	0.000641	0.00202	CcSEcCtD
Methylnaltrexone—Diarrhoea—Losartan—coronary artery disease	0.00064	0.00202	CcSEcCtD
Methylnaltrexone—Nausea—Trandolapril—coronary artery disease	0.000639	0.00201	CcSEcCtD
Methylnaltrexone—Nausea—Enalapril—coronary artery disease	0.000636	0.002	CcSEcCtD
Methylnaltrexone—Vomiting—Perindopril—coronary artery disease	0.000634	0.002	CcSEcCtD
Methylnaltrexone—Abdominal pain—Ramipril—coronary artery disease	0.000634	0.002	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Lisinopril—coronary artery disease	0.000628	0.00198	CcSEcCtD
Methylnaltrexone—Nausea—Telmisartan—coronary artery disease	0.000627	0.00198	CcSEcCtD
Methylnaltrexone—Pain—Lisinopril—coronary artery disease	0.000622	0.00196	CcSEcCtD
Methylnaltrexone—Abdominal pain—Timolol—coronary artery disease	0.00062	0.00195	CcSEcCtD
Methylnaltrexone—Dizziness—Losartan—coronary artery disease	0.000619	0.00195	CcSEcCtD
Methylnaltrexone—Vomiting—Furosemide—coronary artery disease	0.000616	0.00194	CcSEcCtD
Methylnaltrexone—Nausea—Captopril—coronary artery disease	0.00061	0.00192	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Lisinopril—coronary artery disease	0.000595	0.00187	CcSEcCtD
Methylnaltrexone—Vomiting—Losartan—coronary artery disease	0.000595	0.00187	CcSEcCtD
Methylnaltrexone—Nausea—Perindopril—coronary artery disease	0.000592	0.00187	CcSEcCtD
Methylnaltrexone—Naloxone—ESR1—coronary artery disease	0.000585	0.0372	CrCbGaD
Methylnaltrexone—Nausea—Furosemide—coronary artery disease	0.000576	0.00181	CcSEcCtD
Methylnaltrexone—Abdominal pain—Lisinopril—coronary artery disease	0.000575	0.00181	CcSEcCtD
Methylnaltrexone—Nausea—Losartan—coronary artery disease	0.000556	0.00175	CcSEcCtD
Methylnaltrexone—Diarrhoea—Ramipril—coronary artery disease	0.000549	0.00173	CcSEcCtD
Methylnaltrexone—Diarrhoea—Timolol—coronary artery disease	0.000537	0.00169	CcSEcCtD
Methylnaltrexone—Dizziness—Ramipril—coronary artery disease	0.00053	0.00167	CcSEcCtD
Methylnaltrexone—Dizziness—Timolol—coronary artery disease	0.000519	0.00163	CcSEcCtD
Methylnaltrexone—Vomiting—Ramipril—coronary artery disease	0.00051	0.00161	CcSEcCtD
Methylnaltrexone—Vomiting—Timolol—coronary artery disease	0.000499	0.00157	CcSEcCtD
Methylnaltrexone—Diarrhoea—Lisinopril—coronary artery disease	0.000498	0.00157	CcSEcCtD
Methylnaltrexone—Dizziness—Lisinopril—coronary artery disease	0.000481	0.00152	CcSEcCtD
Methylnaltrexone—Nausea—Ramipril—coronary artery disease	0.000476	0.0015	CcSEcCtD
Methylnaltrexone—Buprenorphine—CYP2C19—coronary artery disease	0.000473	0.03	CrCbGaD
Methylnaltrexone—Nausea—Timolol—coronary artery disease	0.000466	0.00147	CcSEcCtD
Methylnaltrexone—Vomiting—Lisinopril—coronary artery disease	0.000463	0.00146	CcSEcCtD
Methylnaltrexone—Nausea—Lisinopril—coronary artery disease	0.000432	0.00136	CcSEcCtD
Methylnaltrexone—Naloxone—ALB—coronary artery disease	0.000261	0.0165	CrCbGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6ST—coronary artery disease	4.9e-05	0.000241	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SDC1—coronary artery disease	4.86e-05	0.000239	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—F2R—coronary artery disease	4.86e-05	0.000239	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—JUNB—coronary artery disease	4.85e-05	0.000238	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PRKCD—coronary artery disease	4.85e-05	0.000238	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PLCB1—coronary artery disease	4.83e-05	0.000238	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGB—coronary artery disease	4.75e-05	0.000234	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR2A—coronary artery disease	4.74e-05	0.000233	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—C3—coronary artery disease	4.74e-05	0.000233	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR7—coronary artery disease	4.73e-05	0.000233	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EDNRB—coronary artery disease	4.71e-05	0.000231	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SULT1E1—coronary artery disease	4.69e-05	0.00023	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—THBS1—coronary artery disease	4.64e-05	0.000228	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PSMB5—coronary artery disease	4.59e-05	0.000225	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PSMA6—coronary artery disease	4.59e-05	0.000225	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—F2—coronary artery disease	4.58e-05	0.000225	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ITGAV—coronary artery disease	4.51e-05	0.000222	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AGT—coronary artery disease	4.5e-05	0.000221	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KNG1—coronary artery disease	4.5e-05	0.000221	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—POMC—coronary artery disease	4.48e-05	0.00022	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CREB1—coronary artery disease	4.48e-05	0.00022	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKR1B1—coronary artery disease	4.47e-05	0.00022	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HK2—coronary artery disease	4.47e-05	0.00022	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AGTR1—coronary artery disease	4.47e-05	0.00022	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EDNRA—coronary artery disease	4.44e-05	0.000218	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CYBA—coronary artery disease	4.42e-05	0.000217	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADRB1—coronary artery disease	4.42e-05	0.000217	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DUSP6—coronary artery disease	4.4e-05	0.000216	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCL2—coronary artery disease	4.39e-05	0.000215	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6R—coronary artery disease	4.37e-05	0.000215	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL10—coronary artery disease	4.37e-05	0.000215	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PLG—coronary artery disease	4.36e-05	0.000214	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PLAT—coronary artery disease	4.33e-05	0.000213	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC27A1—coronary artery disease	4.29e-05	0.000211	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADRB2—coronary artery disease	4.24e-05	0.000208	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CPT1B—coronary artery disease	4.21e-05	0.000207	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LCAT—coronary artery disease	4.21e-05	0.000207	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PRKCE—coronary artery disease	4.19e-05	0.000206	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—JAK2—coronary artery disease	4.18e-05	0.000206	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—BDKRB2—coronary artery disease	4.18e-05	0.000205	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL12—coronary artery disease	4.18e-05	0.000205	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SOCS1—coronary artery disease	4.18e-05	0.000205	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—POMC—coronary artery disease	4.17e-05	0.000205	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—S100B—coronary artery disease	4.17e-05	0.000205	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—F2—coronary artery disease	4.16e-05	0.000204	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6ST—coronary artery disease	4.14e-05	0.000203	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOA4—coronary artery disease	4.13e-05	0.000203	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SOCS3—coronary artery disease	4.13e-05	0.000203	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—JUNB—coronary artery disease	4.1e-05	0.000201	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PLCB1—coronary artery disease	4.09e-05	0.000201	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KITLG—coronary artery disease	4.08e-05	0.0002	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TGFBR2—coronary artery disease	4.08e-05	0.0002	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR7—coronary artery disease	4e-05	0.000197	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PDHA1—coronary artery disease	3.99e-05	0.000196	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GCLM—coronary artery disease	3.99e-05	0.000196	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STAT5A—coronary artery disease	3.98e-05	0.000196	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP3—coronary artery disease	3.98e-05	0.000196	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TXNRD1—coronary artery disease	3.86e-05	0.00019	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP11B2—coronary artery disease	3.86e-05	0.00019	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOB—coronary artery disease	3.85e-05	0.000189	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCL8—coronary artery disease	3.82e-05	0.000188	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ITGAV—coronary artery disease	3.81e-05	0.000187	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC22A3—coronary artery disease	3.8e-05	0.000187	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KNG1—coronary artery disease	3.8e-05	0.000187	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—JAK2—coronary artery disease	3.8e-05	0.000187	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EDN1—coronary artery disease	3.79e-05	0.000186	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—POMC—coronary artery disease	3.79e-05	0.000186	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CREB1—coronary artery disease	3.79e-05	0.000186	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AGTR1—coronary artery disease	3.78e-05	0.000186	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL5—coronary artery disease	3.76e-05	0.000185	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ARNTL—coronary artery disease	3.75e-05	0.000184	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HADH—coronary artery disease	3.75e-05	0.000184	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCL2—coronary artery disease	3.71e-05	0.000182	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CSF2—coronary artery disease	3.7e-05	0.000182	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGF1—coronary artery disease	3.7e-05	0.000182	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6R—coronary artery disease	3.7e-05	0.000182	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL10—coronary artery disease	3.69e-05	0.000181	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PLG—coronary artery disease	3.68e-05	0.000181	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LPL—coronary artery disease	3.68e-05	0.000181	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RPS6KB1—coronary artery disease	3.64e-05	0.000179	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MEF2C—coronary artery disease	3.64e-05	0.000179	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADRB2—coronary artery disease	3.58e-05	0.000176	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PLA2G2A—coronary artery disease	3.55e-05	0.000175	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GPX2—coronary artery disease	3.55e-05	0.000175	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOA2—coronary artery disease	3.55e-05	0.000175	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ITGB3—coronary artery disease	3.55e-05	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRKCE—coronary artery disease	3.54e-05	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—JAK2—coronary artery disease	3.54e-05	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SOCS1—coronary artery disease	3.53e-05	0.000173	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—S100B—coronary artery disease	3.52e-05	0.000173	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GPX4—coronary artery disease	3.51e-05	0.000172	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HK1—coronary artery disease	3.51e-05	0.000172	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCG5—coronary artery disease	3.51e-05	0.000172	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SULT1A1—coronary artery disease	3.51e-05	0.000172	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SOCS3—coronary artery disease	3.49e-05	0.000171	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HADHA—coronary artery disease	3.47e-05	0.00017	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCL8—coronary artery disease	3.47e-05	0.00017	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PPP2CA—coronary artery disease	3.45e-05	0.00017	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KITLG—coronary artery disease	3.45e-05	0.000169	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFBR2—coronary artery disease	3.45e-05	0.000169	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTA1—coronary artery disease	3.43e-05	0.000168	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LPA—coronary artery disease	3.39e-05	0.000167	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PRKCD—coronary artery disease	3.39e-05	0.000166	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STAT5A—coronary artery disease	3.37e-05	0.000165	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP3—coronary artery disease	3.37e-05	0.000165	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR2A—coronary artery disease	3.32e-05	0.000163	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—C3—coronary artery disease	3.31e-05	0.000163	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PLCB3—coronary artery disease	3.28e-05	0.000161	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOB—coronary artery disease	3.26e-05	0.00016	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOA5—coronary artery disease	3.25e-05	0.00016	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCL8—coronary artery disease	3.23e-05	0.000159	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—JAK2—coronary artery disease	3.21e-05	0.000158	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EDN1—coronary artery disease	3.2e-05	0.000157	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—P4HB—coronary artery disease	3.19e-05	0.000157	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL5—coronary artery disease	3.18e-05	0.000156	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HIF1A—coronary artery disease	3.16e-05	0.000155	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AGT—coronary artery disease	3.15e-05	0.000155	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGF1—coronary artery disease	3.13e-05	0.000154	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CSF2—coronary artery disease	3.13e-05	0.000154	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PLA2G1B—coronary artery disease	3.13e-05	0.000154	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LPL—coronary artery disease	3.11e-05	0.000153	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOE—coronary artery disease	3.08e-05	0.000151	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LEP—coronary artery disease	3.08e-05	0.000151	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MEF2C—coronary artery disease	3.08e-05	0.000151	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RPS6KB1—coronary artery disease	3.08e-05	0.000151	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOA1—coronary artery disease	3.05e-05	0.00015	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KDR—coronary artery disease	3.02e-05	0.000148	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ITGB3—coronary artery disease	3e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAPK14—coronary artery disease	3e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—VCAN—coronary artery disease	2.95e-05	0.000145	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ESR1—coronary artery disease	2.94e-05	0.000145	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCL8—coronary artery disease	2.93e-05	0.000144	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALDOA—coronary artery disease	2.93e-05	0.000144	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PPP2CA—coronary artery disease	2.92e-05	0.000143	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FN1—coronary artery disease	2.91e-05	0.000143	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—F2—coronary artery disease	2.91e-05	0.000143	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6ST—coronary artery disease	2.9e-05	0.000142	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NFKBIA—coronary artery disease	2.87e-05	0.000141	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRKCD—coronary artery disease	2.86e-05	0.000141	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—DCN—coronary artery disease	2.84e-05	0.00014	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR2A—coronary artery disease	2.8e-05	0.000138	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—C3—coronary artery disease	2.8e-05	0.000137	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KIT—coronary artery disease	2.78e-05	0.000137	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALDH2—coronary artery disease	2.76e-05	0.000136	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HBA1—coronary artery disease	2.69e-05	0.000132	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3C2A—coronary artery disease	2.69e-05	0.000132	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP2C19—coronary artery disease	2.69e-05	0.000132	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LIPC—coronary artery disease	2.69e-05	0.000132	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOC3—coronary artery disease	2.68e-05	0.000131	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GSK3B—coronary artery disease	2.67e-05	0.000131	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HIF1A—coronary artery disease	2.67e-05	0.000131	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LDLR—coronary artery disease	2.66e-05	0.000131	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AGT—coronary artery disease	2.66e-05	0.000131	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—POMC—coronary artery disease	2.65e-05	0.00013	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CREB1—coronary artery disease	2.65e-05	0.00013	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC9A1—coronary artery disease	2.63e-05	0.000129	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTT1—coronary artery disease	2.63e-05	0.000129	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOE—coronary artery disease	2.61e-05	0.000128	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LEP—coronary artery disease	2.61e-05	0.000128	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CETP—coronary artery disease	2.6e-05	0.000128	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GCLC—coronary artery disease	2.6e-05	0.000128	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL2—coronary artery disease	2.59e-05	0.000127	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6R—coronary artery disease	2.58e-05	0.000127	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOA1—coronary artery disease	2.58e-05	0.000127	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SDC1—coronary artery disease	2.57e-05	0.000126	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KDR—coronary artery disease	2.55e-05	0.000125	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF1—coronary artery disease	2.55e-05	0.000125	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAPK14—coronary artery disease	2.54e-05	0.000125	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—MAPK1—coronary artery disease	2.54e-05	0.000125	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ESR1—coronary artery disease	2.49e-05	0.000122	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—F2—coronary artery disease	2.46e-05	0.000121	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FN1—coronary artery disease	2.46e-05	0.000121	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6ST—coronary artery disease	2.45e-05	0.00012	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NFKBIA—coronary artery disease	2.43e-05	0.000119	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PSMB5—coronary artery disease	2.43e-05	0.000119	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PSMA6—coronary artery disease	2.43e-05	0.000119	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CA—coronary artery disease	2.42e-05	0.000119	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SERPINE1—coronary artery disease	2.42e-05	0.000119	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CTGF—coronary artery disease	2.37e-05	0.000116	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KIT—coronary artery disease	2.35e-05	0.000116	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HMGCR—coronary artery disease	2.35e-05	0.000115	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GOT2—coronary artery disease	2.35e-05	0.000115	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGF2—coronary artery disease	2.34e-05	0.000115	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOS3—coronary artery disease	2.31e-05	0.000113	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GSK3B—coronary artery disease	2.26e-05	0.000111	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—JAK2—coronary artery disease	2.24e-05	0.00011	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—POMC—coronary artery disease	2.24e-05	0.00011	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CREB1—coronary artery disease	2.24e-05	0.00011	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CA—coronary artery disease	2.2e-05	0.000108	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL2—coronary artery disease	2.19e-05	0.000108	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6R—coronary artery disease	2.18e-05	0.000107	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PLCB1—coronary artery disease	2.16e-05	0.000106	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF1—coronary artery disease	2.15e-05	0.000106	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MAPK1—coronary artery disease	2.14e-05	0.000105	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCA1—coronary artery disease	2.09e-05	0.000103	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL8—coronary artery disease	2.05e-05	0.000101	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CA—coronary artery disease	2.05e-05	0.000101	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SERPINE1—coronary artery disease	2.04e-05	0.0001	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GGT1—coronary artery disease	2.03e-05	9.96e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GOT1—coronary artery disease	2.03e-05	9.96e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGF2—coronary artery disease	1.98e-05	9.72e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKT1—coronary artery disease	1.98e-05	9.72e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CASP3—coronary artery disease	1.96e-05	9.63e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOS3—coronary artery disease	1.95e-05	9.59e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6—coronary artery disease	1.95e-05	9.57e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCND1—coronary artery disease	1.91e-05	9.38e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—JAK2—coronary artery disease	1.9e-05	9.32e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CA—coronary artery disease	1.86e-05	9.13e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP9—coronary artery disease	1.85e-05	9.1e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTP1—coronary artery disease	1.82e-05	8.95e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARGC1A—coronary artery disease	1.8e-05	8.87e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT1—coronary artery disease	1.8e-05	8.83e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HMOX1—coronary artery disease	1.8e-05	8.83e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CAT—coronary artery disease	1.77e-05	8.71e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL8—coronary artery disease	1.73e-05	8.51e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOB—coronary artery disease	1.72e-05	8.45e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTM1—coronary artery disease	1.67e-05	8.22e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT1—coronary artery disease	1.67e-05	8.22e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VEGFA—coronary artery disease	1.66e-05	8.17e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CASP3—coronary artery disease	1.66e-05	8.14e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6—coronary artery disease	1.65e-05	8.09e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LPL—coronary artery disease	1.64e-05	8.07e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCND1—coronary artery disease	1.61e-05	7.92e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GPX1—coronary artery disease	1.6e-05	7.88e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP9—coronary artery disease	1.57e-05	7.69e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CD36—coronary artery disease	1.56e-05	7.67e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPP2CA—coronary artery disease	1.54e-05	7.57e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TGFB1—coronary artery disease	1.53e-05	7.5e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT1—coronary artery disease	1.52e-05	7.46e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAPK1—coronary artery disease	1.5e-05	7.36e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTHFR—coronary artery disease	1.48e-05	7.27e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VEGFA—coronary artery disease	1.41e-05	6.91e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AGT—coronary artery disease	1.41e-05	6.91e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOE—coronary artery disease	1.38e-05	6.77e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOA1—coronary artery disease	1.36e-05	6.69e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CA—coronary artery disease	1.3e-05	6.38e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFB1—coronary artery disease	1.29e-05	6.34e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAPK1—coronary artery disease	1.27e-05	6.22e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARG—coronary artery disease	1.2e-05	5.89e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—POMC—coronary artery disease	1.18e-05	5.81e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6—coronary artery disease	1.15e-05	5.65e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CA—coronary artery disease	1.1e-05	5.4e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALB—coronary artery disease	1.08e-05	5.3e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT1—coronary artery disease	1.06e-05	5.22e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NOS3—coronary artery disease	1.03e-05	5.07e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6—coronary artery disease	9.73e-06	4.78e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS2—coronary artery disease	9.44e-06	4.64e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT1—coronary artery disease	8.97e-06	4.41e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CA—coronary artery disease	5.81e-06	2.85e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKT1—coronary artery disease	4.74e-06	2.33e-05	CbGpPWpGaD
